Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events

Cristina Gervasoni, Paola Meraviglia, Simona Landonio, Sara Baldelli, Serena Fucile, Laura Castagnoli, Emilio Clementi, Agostino Riva, Massimo Galli, Giuliano Rizzardini, Dario Cattaneo

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular, women with body weight50 Kg (160±93 vs.71±52 ng/mL, p

Original languageEnglish
Article numbere80242
JournalPLoS One
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 2 2013

Fingerprint

Tenofovir
Drug-Related Side Effects and Adverse Reactions
creatinine
risk factors
Body Weight
bone diseases
drugs
body weight
renal function
Pharmaceutical Preparations
regression analysis
kidneys
bones
Creatinine
Bone
Plasmas
Bone Diseases
Kidney Diseases
Proteinuria
Regression analysis

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Gervasoni, C., Meraviglia, P., Landonio, S., Baldelli, S., Fucile, S., Castagnoli, L., ... Cattaneo, D. (2013). Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. PLoS One, 8(12), [e80242]. https://doi.org/10.1371/journal.pone.0080242

Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. / Gervasoni, Cristina; Meraviglia, Paola; Landonio, Simona; Baldelli, Sara; Fucile, Serena; Castagnoli, Laura; Clementi, Emilio; Riva, Agostino; Galli, Massimo; Rizzardini, Giuliano; Cattaneo, Dario.

In: PLoS One, Vol. 8, No. 12, e80242, 02.12.2013.

Research output: Contribution to journalArticle

Gervasoni, C, Meraviglia, P, Landonio, S, Baldelli, S, Fucile, S, Castagnoli, L, Clementi, E, Riva, A, Galli, M, Rizzardini, G & Cattaneo, D 2013, 'Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events', PLoS One, vol. 8, no. 12, e80242. https://doi.org/10.1371/journal.pone.0080242
Gervasoni C, Meraviglia P, Landonio S, Baldelli S, Fucile S, Castagnoli L et al. Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. PLoS One. 2013 Dec 2;8(12). e80242. https://doi.org/10.1371/journal.pone.0080242
Gervasoni, Cristina ; Meraviglia, Paola ; Landonio, Simona ; Baldelli, Sara ; Fucile, Serena ; Castagnoli, Laura ; Clementi, Emilio ; Riva, Agostino ; Galli, Massimo ; Rizzardini, Giuliano ; Cattaneo, Dario. / Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events. In: PLoS One. 2013 ; Vol. 8, No. 12.
@article{07ae8b4fcf6445879f85decc37cde322,
title = "Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events",
abstract = "Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular, women with body weight50 Kg (160±93 vs.71±52 ng/mL, p",
author = "Cristina Gervasoni and Paola Meraviglia and Simona Landonio and Sara Baldelli and Serena Fucile and Laura Castagnoli and Emilio Clementi and Agostino Riva and Massimo Galli and Giuliano Rizzardini and Dario Cattaneo",
year = "2013",
month = "12",
day = "2",
doi = "10.1371/journal.pone.0080242",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events

AU - Gervasoni, Cristina

AU - Meraviglia, Paola

AU - Landonio, Simona

AU - Baldelli, Sara

AU - Fucile, Serena

AU - Castagnoli, Laura

AU - Clementi, Emilio

AU - Riva, Agostino

AU - Galli, Massimo

AU - Rizzardini, Giuliano

AU - Cattaneo, Dario

PY - 2013/12/2

Y1 - 2013/12/2

N2 - Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular, women with body weight50 Kg (160±93 vs.71±52 ng/mL, p

AB - Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-positive patients with basal creatinine clearance >80 mL/min treated with tenofovir for at least 6 months and with at least one assessment of tenofovir plasma trough concentrations were considered. Tenofovir-associated adverse events were defined as the appearance of pathological proteinuria, worsening of renal function or bone demineralization. By multivariate regression analysis, we found that serum creatinine (p = 0.003) and body weight (p = 0.002) were the factors independently associated with plasma tenofovir concentrations. In particular, women with body weight50 Kg (160±93 vs.71±52 ng/mL, p

UR - http://www.scopus.com/inward/record.url?scp=84891760370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891760370&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0080242

DO - 10.1371/journal.pone.0080242

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e80242

ER -